ライフサイエンスコーパス: between groups

1 conds; 6 months, 20.2+/-6.4 seconds; P=0.001 between groups).

2 321+/-107 m; 6 months, 324+/-116 m; P<0.001 between groups).

3 6+/-0.373 mL/min/kg in the FCM group; P=0.23 between groups).

4 the ApoE epsilon3/epsilon4 group (P = 0.014 between groups).

5 psilon4, polarization was negative (P = 0.08 between groups).

6 ned on FCM (-0.16+/-0.387 mL/min/kg; P=0.020 between groups).

7 DS-VASc risk factors were evenly distributed between groups).

8 0.6%; P = .51) did not differ significantly between groups.

9 atient and graft survival rates were similar between groups.

10 Metabolism of (11)C-MeNER did not differ between groups.

11 Baseline characteristics were similar between groups.

12 at 6 months were not significantly different between groups.

13 orbidity and mortality rates were comparable between groups.

14 , whereas iFGF23 concentrations were similar between groups.

15 Tumor staging was similar between groups.

16 ntages of R0 resections (93%) did not differ between groups.

17 -day mortality, did not differ significantly between groups.

18 re and blood biochemistry were not different between groups.

19 ow normalized to hindlimb weight was similar between groups.

20 howed a statistically significant difference between groups.

21 renal end point did not differ significantly between groups.

22 survival, and patient survival were similar between groups.

23 nicity, and safety appeared to be comparable between groups.

24 th RhD-positive babies (a secondary outcome) between groups.

25 piperacillin plasma concentrations over time between groups.

26 Overall survival was similar between groups.

27 Adverse events were similar between groups.

28 Loss to follow-up was similar between groups.

29 ion, and national cooperative clinical group between groups.

30 Histological findings were comparable between groups.

31 Numbers of adverse events were similar between groups.

32 pgar score (<7) did not differ significantly between groups.

33 fore and after alcohol intake did not differ between groups.

34 spliced genes, with significant commonality between groups.

35 nificant differences in change from baseline between groups.

36 Median FIB-4 at entry was similar between groups.

37 comes, there were no significant differences between groups.

38 obtain QV measurements, which were compared between groups.

39 on (from 62% to 62.3%; P = .01) were similar between groups.

40 tcomes of the 3 questionnaires were compared between groups.

41 and glycerophospholipids strongly overlapped between groups.

42 filling during gastric emptying was compared between groups.

43 ant differences in the rate of complications between groups.

44 fferences in structure and movement dynamics between groups.

45 ant difference in ridge width loss was found between groups.

46 dary end points did not differ significantly between groups.

47 count, and mean platelet volume were similar between groups.

48 vs 12 [<1%] of 3250, p=0.08) did not differ between groups.

49 eristics to account for measured differences between groups.

50 ss >/=15 ml/min per 1.73 m(2) did not differ between groups.

51 al glomerular filtration rate did not differ between groups.

52 bacteria, but concentrations did not differ between groups.

53 oon after pump perfusion) were not different between groups.

54 roBNP levels achieved differed significantly between groups.

55 nically relevant differences after induction between groups.

56 f EEG-vigilance did not differ significantly between groups.

57 er, and cardiovascular profiles were similar between groups.

58 ight change at 12 and 24 months was compared between groups.

59 4-h blood pressure at 3 months, was compared between groups.

60 icacy was defined as 30% absolute difference between groups.

61 her outcome measures were also not different between groups.

62 ar and was no longer significantly different between groups.

63 ces in all-cause or cardiovascular mortality between groups.

64 creatine kinase were infrequent and similar between groups.

65 g and assess differences in neural responses between groups.

66 g stress and sleeping problems were compared between groups.

67 metabolic laboratory findings did not differ between groups.

68 for sensitivity and specificity was compared between groups.

69 ney U test was used to assess the difference between groups.

70 riables to compare symptom levels and trends between groups.

71 Clinical and economic outcomes were compared between groups.

72 parameters and gut microbiota were compared between groups.

73 hospitalisation did not differ significantly between groups.

74 f hypotension and bradycardia did not differ between groups.

75 xygen level-dependent activity were compared between groups.

76 e dynamic causal models, which were compared between groups.

77 of subpopulations of MVs were not different between groups.

78 ments at 18 to 24 months' PMA did not differ between groups.

79 The other antibodies did not differ between groups.

80 rine levels during hypoglycemia were similar between groups.

81 nt was difference in exercise time increment between groups.

82 impairments was not significantly different between groups.

83 %, p=0.145) were not statistically different between groups.

84 justment to account for baseline differences between groups.

85 of stoma closure (80.1% vs 77.3%; P = 0.53) between groups.

86 erences in hospital complications were noted between groups.

87 mean arterial pressure at 1, 24, or 48 hours between groups.

88 the actuarial 15-year PS rates were similar between groups.

89 e primary end point at 12 months was similar between groups.

90 rom 39% to 58%), increasing the survival gap between groups.

91 vents, there were no significant differences between groups.

92 tly mild and occurred at a similar frequency between groups.

93 Rates of other adverse events did not differ between groups.

94 hickening were included to study differences between groups.

95 dental diseases did not significantly differ between groups.

96 group than in the placebo group (difference between groups 0.071, 95% CI 0.002 to 0.139; p=0.044).

97 e serotype UTIs did not differ significantly between groups (0.046 mean episodes in the vaccine group

98 95% CI, -0.2 to -0.0]; P = .008) (difference between groups, -0.0 [95% CI, -0.1 to 0.1]; P = .88).

99 nts [95% CI, -5.5 to -1.7]); mean difference between groups, -0.4 (95% CI, -3.4 to 2.7; P = .82).

100 glomerular filtration rate or graft failure between groups 1 and 2 (41.5 +/- 18 vs 41.4 +/- 22 mL/mi

101 y [95% CI, 0.2 to 2.2]; P = .02) (difference between groups, 1.6 cups per day [95% CI, 0.2 to 3.0 cup

102 requesting a change in resuscitation status between groups (11.2% vs 9.4%; p = 0.666).

103 We saw no difference in hospital admissions between groups (12.5% in the co-trimoxazole group vs 17.

104 -related serious adverse events were similar between groups (13 [11%] in the ceritinib group vs 12 [1

105 r adjunctive risperidone was low and similar between groups (17% and 14%, respectively).

106 127.5 hours, respectively; median difference between groups, 17.0 hours [95% CI, 4.0 to 33.2 hours];

107 e of pesticide self-poisoning did not differ between groups (293.3 per 100 000 person-years of follow

108 erse cardiovascular event rates were similar between groups (30.6% versus 32.6%), with differences ap

109 Pulmonary complication rate did not differ between groups: 34.2% (OE) versus 35.6% (MIE) (P = 0.669

110 nces in endothelial stretching were observed between groups (37% versus 37% versus 31%; P=0.62).

111 hange in knowledge quiz score did not differ between groups (4.9% vs 0.6%; P = 0.084), despite a sign

112 Study, baseline characteristics were similar between groups: 50% had diabetes mellitus, 41% were wome

113 Mean mitral valve gradients were similar between groups (6.4 +/- 2.3 mm Hg vs. 5.8 +/- 2.7 mm Hg;

114 t-reported upper respiratory tract illnesses between groups (625 for high-dose vs 600 for standard-do

115 Mean duration of antibiotics did not differ between groups (7.2 days [SD 5.1] in the POCT group vs 7

116 baseline to month 12 differed significantly between groups (+7.07+/-6.22% versus +1.85+/-5.60%; P=0.

117 ative pulmonary complications did not differ between groups (8 patients [7.1%] in the control group v

118 Grade 3-4 anaemia did not differ between groups (8.1% vs 8.3%, p=0.93), but grade 3-4 neu

119 as not statistically significantly different between groups (91.7 in the hydrocortisone group vs 91.4

120 of bleeding events at 1-month postdischarge between groups, adjusting for bleeding risk factors.

121 PANSS positive score did not differ between groups after 12 weeks (adjusted mean change -5.0

122 2.7% (N=89), without significant differences between groups after accounting for dropout.

123 tion demonstrated no significant differences between groups after adjustment.

124 g in the cortex did not differ significantly between groups after age adjustment.

125 itive impairment [PCI] subscale): difference between groups after intervention (T2) and 6 months late

126 tinent, lapse, and relapse were not observed between groups (all between P = .06 and .75).

127 A two-way between-groups analysis showed that there was a signific

128 No differences were found between groups and controls except for HOMA and insulin

129 l striatum and dorsal striatum were compared between groups and correlated with craving and BMI chang

130 CSF tau levels were compared between groups and correlated with digital histology mea

131 Comparison of MRI findings between groups and correlation between clinical, serolog

132 O-binding potential (DeltaBPND) was compared between groups and correlations with MRS glutamate, subc

133 ree [7%] of 41 with opicinumab) were similar between groups and no significant effects on brain MRI m

134 -pons SI ratios were calculated and compared between groups and relative to total cumulative gadolini

135 identified 35 genes differentially expressed between groups and surviving adjustment for false discov

136 rombosis, a safety indicator, did not differ between groups and was low in both treatment groups.

137 ared across the entire white matter skeleton between groups, and correlated with cognitive measures a

138 rocessing of emotional stimuli were compared between groups, and differences were explored for relati

139 and severity of adverse events were similar between groups, and few participants discontinued treatm

140 Dropout rates did not differ between groups, and treatment-emergent adverse events we

141 Aggressive interactions between groups are frequent in human societies and can b

142 s measured by the EORTC QLQ-C30, was similar between groups, as no clinically relevant differences (1

143 d quality-of-life scores also did not differ between groups at 1 year (standard 2.0 [SD 2.7] vs mesh

144 s from baseline did not differ significantly between groups at 3 months (adjusted difference, -0.08%;

145 es were safety and difference in improvement between groups at 3 months in the on-medication treated

146 Dyspnea relief by Likert scale was similar between groups at 8 h (25% moderately or markedly improv

147 No significant differences existed between groups at baseline; 61% of the participants had

148 x hazards analysis was used to compare rates between groups at discrete time points.

149 mance on cognitive measures was no different between groups at the 5-year evaluation.

150 as no difference in sustained reading speeds between groups (beta = 0.99, 95% CI: -41.8, 43.8, P = .9

151 fold clustering did not differ significantly between groups, blocking D2Rs significantly changed the

152 E was 9.1% overall (104 of 1137) and similar between groups (blunt trauma, 9% [n = 73] vs penetrating

153 econdary outcomes were statistically similar between groups but tended to favor clindamycin.

154 ) were statistically significantly different between groups but were not clinically relevant.

155 and GFRs for each time period were compared between groups by using hierarchic regressions or chi(2)

156 GP:T and DN:P SI ratios were compared between groups by using the analysis of variance and wer

157 ing for the differences in size and coupling between groups can substantially improve organic carbon

158 When compared between groups, clinical parameters did not show any sta

159 hy responses was not significantly different between groups, decreasing by 11 muV for the OAC alone g

160 The between-groups differences, however, were not statistica

161 nary dysplasia, the difference in flow rates between groups diminished.

162 e frequency of adverse events did not differ between groups during gestation or at delivery: 24 women

163 howed no differences in the incidence of CRC between groups during the follow-up period (log-rank, 0.

164 everity of adverse events was mostly similar between groups except for nausea, which occurred less fr

165 d virological characteristics did not differ between groups except median CD4 cell percentage, which

166 stoperative morbidity was also not different between groups (FFT: 12% vs LFT: 8%, P = 0.266).

167 col analysis showed a significant difference between groups for both eyes (OD and OS), and for the wo

168 re were also no differences within groups or between groups for changes in total or HDL cholesterol o

169 HLD/ETO, we found no significant differences between groups for MDRO or bacteria contamination.

170 ere no significant differences in prevalence between groups for PTSD (adjusted odds ratio 0.92, 95% C

171 RPE parameters and total retinal thicknesses between groups for the different areas and their corresp

172 in and physical activity levels were similar between groups from days 7 to 10.

173 analysis, the composite endpoint was similar between groups (hazard ratio [HR]: 0.820; p = 0.27), as

174 We did not detect a significant difference between groups in 30-day all-cause mortality (16.7% with

175 e, we did not detect significant differences between groups in BP or serum levels of markers of infla

176 ant or statistically significant differences between groups in CIS-fatigue score at 4 weeks (mean dif

177 CGI-I score, with no significant differences between groups in either clinical (CGI-I: relative risk

178 because there was no significant difference between groups in mean daily blood glucose concentration

179 However, genetic differentiation between groups in Papua New Guinea is much stronger than

180 There were no significant differences between groups in patients' growth parameters, use of 3-

181 etect a statistically significant difference between groups in percentage of body fat gain over 12 mo

182 There was no difference between groups in serious adverse events, grade 3 or 4 a

183 afety concerns and there were no differences between groups in serious or other adverse events.

184 longer than 5 years, there was no difference between groups in subsequent actuarial PS, GS, and DCGS.

185 There was no difference between groups in terms of age (P = .13) or sex (P = .81

186 There were no differences between groups in terms of gender, age, smoking habits a

187 No significant differences were noted between groups in terms of volume to fullness, satiety,

188 There were significant differences between groups in the acute success of ablation (82% ver

189 -23]; p<0.0001), but there was no difference between groups in the average duration of treatment (27.

190 The difference between groups in the change in IBDQ-B scores between th

191 The primary endpoint was the difference between groups in the change in the Inflammatory Bowel D

192 However, the difference between groups in the evolution of MPOD measured by HRA

193 No differences were observed between groups in the incidence of acute graft-versus-ho

194 hological complete response (ypT0/is, ypN0), between groups in the intention-to-treat population (two

195 The primary endpoint was the difference between groups in the number of patients classified as t

196 There was no difference between groups in the number of telephone communications

197 There was no difference between groups in the percentage of infants with IgE-med

198 There was no difference between groups in the rate of acute or chronic rejection

199 ere was no clinically significant difference between groups in the rates of serious adverse events an

200 rial was non-inferiority in mean differences between groups in their daily blood glucose concentratio

201 There were no significant differences between groups in time taken to achieve tooth alignment

202 There were no significant differences between groups in time to extubation alive (hazard ratio

203 plan-Meier curve was significantly different between groups in time to first syncope: 29.2 months (95

204 d from diffusion tensor imaging was compared between groups in whole brain, lobar and vertex-based an

205 in number of laboratory-confirmed infections between groups (incidence rate ratio [RR], 0.97; 95% CI,

206 h were statistically significantly different between groups included free fatty acids, bile acids, an

207 Change in satisfaction differed between groups (intervention, 1.2% vs control, -4.9%; P

208 Between groups, iron absorption was greater from the FeF

209 he temperature-dependent exchange of animals between groups is shown to reproduce a second-order crit

210 Although LV ejection fraction was comparable between groups, longitudinal peak was reduced compared w

211 of 24 months, ADCS ADL scores did not differ between groups (mean difference, 2.34 [95% CI, -5.27 to

212 cant difference in the DRI score at 6 months between groups (mean score, 29.8 in the nail group vs 33

213 x 6-mm scans was also considerably different between groups: mean (SD) vessel density of the deep ret

214 urces, social stratification or connectivity between groups, might have led to the early differences

215 MMA and their changes differed significantly between groups (MMA changes: -0.169 +/- 0.340 compared w

216 e events during supplementation were similar between groups (MMN-0 = 20 [1 death]; MMN-6 = 21 [1 deat

217 s adverse events were infrequent and similar between groups (nine [4%] in the EUC plus HAP group vs t

218 rition and adverse events (AEs) were similar between groups, no serious AEs (n=2 exercise, n=3 handwr

219 The structural comparison between groups of GASright dimers of different stabiliti

220 tcome of therapy in terms of tooth mortality between groups of patients treated with conventional sca

221 alculated rates of progression to HGD or EAC between groups of patients with irregular Z line (n = 16

222 ary outcome) was not statistically different between groups on an intent-to-treat basis (p = 0.25).

223 Childhood wasting did not differ between groups (OR 0.92, 95% CI 0.75-1.12), although imp

224 d mixed models analyses assessed differences between groups over time.

225 difference in the number of episodes of pain between groups ( P = 0.81) or in the number of teeth ext

226 Fiber intakes were significantly different between groups (P < 0.001).

227 significant difference in membrane thickness between groups (P <0.001).

228 There was no difference in liver attenuation between groups (P = .12).

229 as not statistically significantly different between groups (P = .33).

230 ts from the SDQ did not differ significantly between groups (P = .78).

231 Visual outcomes were similar between groups (P = .90).

232 Sympathetic BRS was similar between groups (P = 0.927), whereas cardiac BRS (cBRS) w

233 Other disease-risk biomarkers were similar between groups (p>0.05).

234 Although asthma control test did not differ between groups (P=.288), patients with paucigranulocytic

235 essed as z score or millimeters, was similar between groups (P=0.07 and 0.47, respectively).

236 , while core bereavement scores were similar between groups (p=0.269).

237 terventions (94.2%), and this did not differ between groups (P=0.274).

238 primary endpoint of exercise time increment between groups (PCI minus placebo 16.6 s, 95% CI -8.9 to

239 There was no difference in anxiety levels between groups postoperatively.

240 ction by day 30 after surgery did not differ between groups (range, 11%-20%; P=0.46).

241 ations, whereas no differences were observed between groups receiving wild-type or NLRX1(-/-) regulat

242 There was no difference between groups regarding demographics and predisposing f

243 There was no difference between groups regarding need for additional eyelid surg

244 There were no differences between groups regarding the rate of microcephaly, neuro

245 The recall rate was similar between groups (RR, 0.95; 95% CI: 0.84, 1.06), whereas t

246 Within- and between-groups second level analyses were performed.

247 n of the mean changes (delta) in the markers between groups showed that TGF-beta1 and TIMP-1 levels w

248 neonatal deaths did not differ significantly between groups (six [2.0%] vs three [1.0%] neonatal deat

249 Staff vaccination rates did not differ between groups, so analyses focused on the high-dose ver

250 f significant differences in [(18)F]FEPPA VT between groups suggests that microglial activation is no

251 differences in extent of inducible ischemia between groups (summed difference score mean [+/-SD]: 2.

252 ons of patients with major or minor bleeding between groups that did vs did not receive anticoagulant

253 with a 3% or greater difference in incidence between groups that were more frequent with treatment of

254 Despite these jumps between groups, the major axes of within-group bill-shap

255 mass index, and type of sports participation between groups, the risk of 2 or more abnormal menstrual

256 characteristics did not differ significantly between groups; the mean Mini-Mental State Examination s

257 Pneumonia was uncommon, with no differences between groups; there was no difference in other serious

258 ne to week 6, but changes were not different between groups.This combination probiotic improved rhino

259 nsistent and differences were nonsignificant between groups throughout the study.

260 g treatment failure criteria, which differed between groups (tight control group before and after ran

261 ations and all-cause mortality were compared between groups using a Cox regression model controlling

262 ls of cytokines and chemokines were compared between groups using multivariate logistic regression an

263 We compared variables between groups using the Wilcoxon Signed Rank test and t

264 Two-year outcomes were compared between groups using univariate and multivariable Cox pr

265 r 100000 for Cuban men, but rate differences between groups vary substantially, with Puerto Ricans ex

266 The mean change in plasma IL-6 levels between groups was -0.79 log10 units (-2.06 to 0.48) in

267 mean difference in the AE-QoL and DLQI score between groups was -17.6 (P < .001) and -7.2 (P < .001),

268 The mean difference in final BCVA between groups was 0.22 logMAR (95% confidence interval:

269 of change in the use of oral anticoagulation between groups was 3.28 (95% CI 1.67-6.44; adjusted p va

270 Absolute difference in the change between groups was 9.1% (95% CI 3.8-14.4); odds ratio of

271 However, power to detect differences between groups was low.

272 The 95% CI adjusted difference between groups was more than the prespecified acceptable

273 mean difference in direct health care costs between groups was pound107.53 ( pound155.74 interventio

274 Non-inferiority between groups was shown if the lower bound of the 98.34

275 Our main outcome measures for comparison between groups were (1) the average and minimum GCC thic

276 Differences between groups were compared by using the chi(2) test.

277 Comparisons within and between groups were done with the use of mixed-effects m

278 Significant outcome differences between groups were found in operative and anesthesia ti

279 he only significant preoperative differences between groups were higher percent of clopidogrel-treate

280 No differences in adverse events between groups were identified.

281 Univariate comparisons between groups were made with a combined fold change >/=

282 After T2, differences between groups were no longer significant.

283 Differences between groups were significant and clinically meaningfu

284 airwise comparisons of beta diversity values between groups were significantly different (P < 0.05),

285 Differences between groups were still significant at 2 years.

286 Associations did not differ between groups when stratified by urine albumin-to-creat

287 uptake and lactate output rates were similar between groups, whereas amino acid uptake was lower in I

288 uptake and lactate output rates were similar between groups, whereas amino acid uptake was significan

289 rease in cardiac output and CVC were similar between groups, whereas FVC increased to a greater exten

290 fluid showed significantly distinct profiles between groups with 125 differentially expressed protein

291 Admixture between groups with different ancestry profiles was perv

292 hazards of hospital mortality were evaluated between groups with multivariable analysis methods.

293 Differences were most pronounced between groups with no exposure and groups with low expo

294 women, 8.6%; minorities, 9.6%) were similar between groups with no significant differences after ris

295 No differences were observed between groups with regard to number of, reasons for, or

296 There were no differences between groups with regard to patient characteristics: a

297 Although there was no difference between groups with respect to common postoperative comp

298 T1-weighted whole-brain images were assessed between groups with voxel-based morphometry, using ANCOV

299 m in which animals are iteratively exchanged between groups, with a probability of exchanging groups

300 and change in left thalamus volume differed between groups, with a significant positive correlation